Chemed (NYSE:CHE – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $23.30-23.70 for the period, compared to the consensus estimate of $23.52. Chemed also updated its FY 2024 guidance to 23.300-23.700 EPS.
Analyst Upgrades and Downgrades
CHE has been the topic of several research analyst reports. Oppenheimer boosted their target price on shares of Chemed from $625.00 to $650.00 and gave the stock an outperform rating in a research report on Thursday, February 29th. Royal Bank of Canada lifted their price target on shares of Chemed from $604.00 to $712.00 and gave the company an outperform rating in a research report on Monday, March 4th.
Chemed Price Performance
Chemed (NYSE:CHE – Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $6.60 earnings per share for the quarter, beating the consensus estimate of $6.25 by $0.35. Chemed had a return on equity of 32.29% and a net margin of 12.03%. The company had revenue of $585.90 million during the quarter, compared to the consensus estimate of $586.64 million. During the same period in the previous year, the firm posted $5.39 EPS. Chemed’s revenue was up 7.2% on a year-over-year basis. Sell-side analysts expect that Chemed will post 21.99 EPS for the current fiscal year.
Chemed Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Monday, February 26th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date was Friday, February 23rd. Chemed’s dividend payout ratio is presently 8.93%.
Insider Buying and Selling
In related news, EVP Spencer S. Lee sold 2,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $641.65, for a total transaction of $1,283,300.00. Following the completion of the sale, the executive vice president now directly owns 20,760 shares of the company’s stock, valued at approximately $13,320,654. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Michael D. Witzeman sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $643.14, for a total value of $1,704,321.00. Following the sale, the chief financial officer now owns 2,882 shares in the company, valued at approximately $1,853,529.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Spencer S. Lee sold 2,000 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $641.65, for a total value of $1,283,300.00. Following the completion of the sale, the executive vice president now directly owns 20,760 shares of the company’s stock, valued at $13,320,654. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,808 shares of company stock valued at $10,184,531. Corporate insiders own 3.32% of the company’s stock.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also
- Five stocks we like better than Chemed
- How to invest in blue chip stocks
- High-Yield Texas Instruments Could Hit New Highs Soon
- What does consumer price index measure?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Best Stocks Under $10.00
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.